Drucken
Artikel, Notizen und Markierungen werden geladen... Bitte um etwas Geduld.

Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).

Art. 2 Definitions 15

In this Or­din­ance:

a.
clin­ic­al tri­al means a re­search pro­ject in­volving in­di­vidu­als that pro­spect­ively as­signs them to un­der­go a health-re­lated in­ter­ven­tion in or­der to study its ef­fects on health or on the struc­ture and func­tion of the hu­man body;
b.
health-re­lated in­ter­ven­tion means a pre­vent­ive, dia­gnost­ic, thera­peut­ic, pal­li­at­ive or re­hab­il­it­at­ive meas­ure in­vest­ig­ated in a clin­ic­al tri­al;
c.
min­im­al risks and bur­dens means risks and bur­dens, which, in terms of in­tens­ity and qual­ity, and tak­ing in­to ac­count the vul­ner­ab­il­ity of the par­ti­cipants and the spe­cif­ic cir­cum­stances, will have only a slight and tem­por­ary im­pact on the par­ti­cipants’ health; in par­tic­u­lar, min­im­al risks and bur­dens may be as­so­ci­ated with:
1.
sur­veys and ob­ser­va­tions,
2.
peri­pher­al ven­ous or ca­pil­lary blood sampling and skin punch biopsies of lim­ited ex­tent,
3.
re­mov­ing or col­lect­ing bod­ily sub­stances without in­vas­ive in­ter­ven­tions, in par­tic­u­lar, saliva, ur­ine and stool samples,
4.
tak­ing swabs,
5.
mag­net­ic res­on­ance ima­ging scans without a con­trast me­di­um, ul­tra­sound ex­am­in­a­tions or elec­tro­grams,
6.16
ex­am­in­a­tions us­ing ion­ising ra­di­ation, provided that the ef­fect­ive dose is be­low 5 mSv per re­search pro­ject and per per­son con­cerned and:
the medi­cin­al product used is au­thor­ised or ex­empt from au­thor­isa­tion, or
the devices un­der Art­icle 1 MedDO17 bear con­form­ity mark­ings and no con­trast me­di­um is used;
d.
spon­sor means a per­son or in­sti­tu­tion headquartered or rep­res­en­ted in Switzer­land that takes re­spons­ib­il­ity for or­gan­ising a clin­ic­al tri­al, and in par­tic­u­lar for the ini­ti­ation, man­age­ment and fin­an­cing of the tri­al in Switzer­land;
e.
in­vest­ig­at­ormeans a per­son re­spons­ible in Switzer­land for the con­duct of a clin­ic­al tri­al and for the pro­tec­tion of the par­ti­cipants at the tri­al site; an in­vest­ig­at­or who takes re­spons­ib­il­ity for or­gan­ising a clin­ic­al tri­al in Switzer­land is also a spon­sor.

15 Amended by An­nex 2 No 2 of the O of 1 Ju­ly 2020 on Clin­ic­al Tri­als with Med­ic­al Devices, in force since 26 May 2021 (AS 2020 3033).

16 Amended by An­nex 2 No 2 of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294).

17 SR 812.213